|
Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer Clinical research trials and Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer. Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer clinical trial. Test subjects typically obtain the finest healthcare available for their Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer  Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer
Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer
For Condition: Breast Cancer
Status: Recruiting
Sponsor(s): National Cancer Research Institute (NCRI) ,
Synopsis: RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of raloxifene and goserelin may be effective in preventing breast cancer. PURPOSE: Randomizedpilot study to study the effectiveness of combining raloxifene and goserelin in preventing breast cancer in women who have a family history of breast cancer.
Details: OBJECTIVES: - Compare the feasibility of raloxifene and goserelin versus no medical intervention in women at high genetic risk for developing breast cancer. - Compare the incidence of adverse effects in patients treated with these regimens. - Compare the effect of these regimens on bone density, biochemical markers of bone turnover, and lipid profiles in these patients. - Compare the quality of life of patients treated with these regimens. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center. Patients are randomized to one of two treatment arms. - Arm I: Patients receive goserelin subcutaneously once every month and oral raloxifene daily for 6-12 months. - Arm II: Patients are screened for breast cancer every 6 months. In both arms, patients undergo annual mammograms. Quality of life is assessed at baseline and at 1, 3, 6, and 12 months. Patients are followed for 5 years. PROJECTED ACCRUAL: A total of 150 patients (75 per treatment arm) will be accrued for this study.
Eligibility:
Study Type: Interventional, Prevention
Minimum Age/Maximum Age: 30 Years/45 Years
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - High genetic risk of developing breast cancer defined as one or more of the following: - BRCA1 or BRCA2 germ-line mutation - First-degree relative of known BRCA1 or BRCA2 mutation carrier - Family with 4 or more relatives diagnosed with female or male breast cancer or ovarian cancer before the age of 60 - Two first-degree relatives diagnosed with breast cancer before the age of 40 - p53 germ-line mutation (classical Li-Fraumeni syndrome (LFS) only) - First-degree relative of a carrier in a family with classical LFS - Risk equivalent to any of the above confirmed by clinical geneticist - No evidence of breast cancer by mammography - Suspicious lesions must be confirmed as non-malignant - No prior breast cancer - No prior prophylactic mastectomy - No plan for alternative prevention measures within the next 12 months - Hormone receptor status: - Not specified PATIENT CHARACTERISTICS: Age: - 30 to 45 Sex: - Female Menopausal status: - Premenopausal (follicle-stimulating hormone in premenopausal range if not menstruating) Performance status: - Not specified Life expectancy: - More than 10 years (excluding breast cancer risk) Hematopoietic: - Not specified Hepatic: - Adequate liver function Renal: - Adequate renal function Cardiovascular: - No prior deep vein thrombosis Pulmonary: - No prior pulmonary embolism Other: - Not pregnant - Fertile patients must use effective nonhormonal contraception - No psychological disorder that would preclude study compliance - No prior malignancy within the past 5 years except curatively treated nonmelanoma skin cancer or cervical cancer PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - Not specified Endocrine therapy: - No concurrent hormonal therapy (e.g., oral contraception or hormone replacement therapy) Radiotherapy: - Not specified Surgery: - See Disease Characteristics Other: - At least 30 days or 5 half-lives since prior investigational drugs - No concurrent anticoagulants
Total Enrollment:
Location and Contact Information:
Overall Study Official:
AnthonyHowell, Study Chair, Christie Hospital N.H.S. Trust
Christie Hospital N.H.S. Trust *Recruiting*
Manchester, England, M20 4BX
United Kingdom
Recruiting Anthony Howell 44-161-446-8037
Additional Information:
Study ID Numbers: CDR0000069233; EU-20053,NCRI-IBIS-RAZOR,UKCCCR-IBIS-RAZOR
Study Start Date:
Record last reviewed: March 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00031850
Other Breast Cancer Studies:
1. A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer
2. Peripheral Stem Cell Transplantation Plus Monoclonal Antibody Therapy in Treating Patients With High-Risk Hematologic Cancer, Refractory Breast or Kidney Cancer, or Melanoma
3. Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
4. Study of Inhaled Doxorubicin (Adriamycin) to Treat Advanced Lung Cancer
5. Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study
Related Studies:
Other Breast Cancer Clinical Trials
Other England Clinical Trials
Other Manchester Clinical Trials
Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer
|
|
|
|
|
|
|
|
